Friday, 6 November 2020

Biogen Alzheimer’s drug in doubt after criticism from expert panel

Scientists express scepticism of trial data and US regulatory process at fiery hearing

from International homepage https://ift.tt/3p3EFGL

No comments:

Post a Comment

At an ex-OpenAI researcher's influential lab, $500,000 salaries aren't enough to fix a talent 'bottleneck'

METR's CEO, Beth Barnes, and president, Chris Painter. METR METR, a Berkeley lab started by an ex-OpenAI researcher, has grown into a pr...